Cardiovascular risk stratification according to SCORE risk* and EULAR modified SCORE risk† in 95 rheumatoid arthritis patients without cardiovascular events, diabetes mellitus or severe chronic kidney disease‡
| Cardiovascular risk | EULAR modified SCORE§ | |||||
|---|---|---|---|---|---|---|
| SCORE* n | n | CACS | ||||
| Normal‡ (CACS 0) n=40 (%) | Low–moderate (CACS 1–100) n=38 (%) | Moderate–high (CACS >100–400) n=9 (%) | High (CACS >400) n=8 (%) | |||
| Low (<1%) | 21 | 21 | 16/21 (76.2) | 5/21 (23.8) | 0/21 (0.0) | 0/21 (0.0) |
| Moderate (≥1% and <5%) | 63 | 60 | 22/60 (36.7) | 26/60 (43.3) | 6/60 (10.0) | 6/60 (10.0) |
| High (≥5% and <10%) | 9 | 10 | 1/10 (10.0) | 5/10 (50.0) | 3/10 (30.0) | 1/10 (10.0) |
| Very high (≥10%) | 2 | 4 | 1/4 (25.0) | 2/4 (50.0) | 0/4 (0.0) | 1/4 (25.0) |
| High plus very high | 11 | 14 | 2/14 (14.3) | 7/14 (50.0) | 3/14 (21.4) | 2/14 (14.3) |
EULAR modified SCORE risk stratification according to the Coronary Artery Calcification Score (CACS).
*According to SCORE for the general population.23 ,24
†Modified SCORE for rheumatoid arthritis: according to the EULAR recommendations.8
‡Six patients with moderate modified SCORE and three with high and/or very high modified SCORE had type 2 diabetes or severe chronic kidney disease and, due to this, met definitions for very high cardiovascular risk and were excluded from the analysis.
§Modified SCORE was calculated by the application of a multiplier factor of 1.5 in those patients with two of three criteria: disease duration >10 years, rheumatoid factor and/or anticyclic citrullinated peptide antibody positivity, and presence of extra-articular manifestations.8
EULAR, European League Against Rheumatism; SCORE, Systematic Coronary Risk Evaluation.